SUMMARY
LEVATED serum cholesterol levels play a major role in the development of atherosclerosis.1),2) A strategy used recently to lower serum cholesterol is the inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (mevalonate: NADP+oxireductase [CoA acylating], EC 1.1.1.34), the enzyme catalyzing the conversion of HMG-CoA to mevalonic acid. Inhibition of this enzyme produces an increase in mRNA for the low density lipoprotein (LDL) receptor in the liver3) which results in increased receptor mediated clearance of LDL,4) the major cholesterol transport lipoprotein in human plasma. Endo and coworkers first reported that mevastatin, a fungal metabolite of Penicillium citrinum, was a strong competitive inhibitor of HMGCoA reductase.5),6) This compound was shown to reduce plasma cholesterol levels in several species including humans.7) Subsequently, other naturally occurring HMG-CoA reductase inhibitors were isolated, including lovastatin and simvastatin.
These compounds are inactive prodrugs that are enzymatically transformed in vivo to their metabolically active form.8) Pravastatin (SQ 31,000) is a competitive inhibitor of HMG-CoA reductase derived from Nocardia autotrophica.9) As opposed to mevastatin, lovastatin, and simvastatin, this drug does not require in vivo transformation to exert its action, and it is more water soluble than the other analogues.10)
Familial hypercholesterolemia (FH) is an inherited disease in which the LDL receptor pathway is defective. In its homozygous state, FH is characterized by very high levels of serum cholesterol and accelerated atherosclerosis.11),12) An animal model of this disease is the Watanabe Heritable Hyperlipidemic (WHHL) rabbit which develops hyperlipidemia due to a severe deficiency of functional LDL receptors.13)-16) The lack of receptor is responsible for both a reduced uptake of LDL and an overproduction of LDL from intermediate density lipoproteins (IDL), which are also cleared by the LDL receptor.11),17) Thus, WHHL rabbits may also over-produce very low density lipoproteins (VLDL), the precursor of IDL, because hepatic cholesterol synthesis is not suppressed by LDL-receptor mediated events. In the arterial wall, the accumulation of lipids seems to be independent of cellular LDL receptors18) and WHHL rabbits develop marked aortic atherosclerosis at a premature age.13),19),20) The purpose of these studies was to determine the effects of pravastatin on serum lipids and the atherosclerotic process in an animal model that lacks the LDL receptor. pravastatin groups, respectively. None of these differences were significant. There were significant positive correlations in the 1-year study between serum cholesterol levels and either aortic cholesterol levels or the proportion of the aortic surface covered by plaque [ Table I ].
These correlations were found in both control and treated animals, suggesting that these factors are mechanistically related. Microscopic inspection of the four coronary arteries from each heart examined at 3 levels showed atherosclerotic plaques in only 2 of 8 controls and 4 of 12 of the treated group. There was wide variation in the severity of the lesions and no qualitative differences were apparent between groups. Cross-sectional area analysis confirmed this marked variation and lack of differences as shown by the representative results in Table II from the left circumflex coronary artery.
DISCUSSION
WHHL rabbits lack functional LDL receptors and are animal models of homozygous FH.13)-16) These animals develop atherosclerosis which is histologically similar to that in humans.19) The hyperlipidemia has been ascribed to deficient removal of LDL from the circulation20) and an increased Jpn.
Heart J. S eptember 1991 conversion of VLDL and IDL to LDL. Inhibition of cholesterol synthesis by lovastatin has been shown to stimulate LDL receptor activity in normal animals,3),26),27) which is preceded by an increase in receptor mRNA.4) Whether pravastatin will similarly influence LDL receptor activity of WHHL rabbits thereby modulating clearance of LDL has not been definitely shown. This problem was not the scope of the present study.
Though the hypolipidemic effects of bile chelating resins have been ascribed to the induction of LDL receptors,26),27) treatment of patients with homozygous FH with these agents or nicotinic acid results in regression of xanthomatous lesions.28),29) These observations suggest that mechanisms other than the up regulation of LDL receptors could be involved. Thus, we undertook the present studies to determine the effects of a competitive inhibitor of cholesterol synthesis on serum cholesterol and atherosclerosis in the animal model of homozygous FH.
Cholesterol levels in treated and untreated animals decreased with age. This age-related effect has been shown previously.30),31) Pravastatin consistently lowered serum cholesterol levels (p<0.001, Fig. 1a ) when given in a single, daily oral dose of 50mg/kg body weight. A dosage of 5mg/kg of the HMG-CoA reductase inhibitor, lovastatin, has been shown to significantly reduce plasma cholesterol (p<0.005) in WHHL rabbits but not the extent of aortic atherosclerosis.32) By comparison, the clinically effective dosage of these agents to lower plasma cholesterol in humans varies from 10-50mg/day.
Concurrent studies in our laboratory have shown that hepatic cholesterol synthesis in vivo in WHHL rabbits is significantly reduced by pravastatin for up to 24 hours at the same dose utilized in these experiments.33) Recently, Arad et al showed that lovastatin decreases synthesis of apolipoprotein B.34) Wyne et al35) reported that lovastatin reduced apolipoprotein E secretion from rat granulosa cells. Considered together, these studies suggest that inhibition of HMG-CoA reductase may alter apolipoprotein B & E regulation resulting in decreased formation of cholesterol rich lipoproteins. This may account for the pravastatin effect in these animals.
Although triglyceride levels were not significantly reduced by pravastatin treatment, levels in the treated animals were on the average lower than in controls (Fig. 2b) . Tsujita et al9) suggested that treatment with the drug produces a substitution of cholesterol by triglycerides in VLDL, a hypothesis that may explain the lack of significant effects of pravastatin on serum triglyceride levels.
Of the three parameters for aortic atherosclerosis that we monitored, aortic cholesterol showed the steepest rise over the period of the study. The effect of pravastatin treatment was most apparent for this parameter.
Our data do not preclude a direct inhibitory effect of pravastatin on aortic cholesterol synthesis. However, the correlations found between serum cholesterol and aortic cholesterol and between serum cholesterol and the percent of the aortic surface area showing plaque indicate that serum cholesterol is the determinant of aortic atherosclerosis in these animals. This is consistent with the demonstration by Carew et al32) that modified LDL cholesterol is degraded by macrophages in the wall of the aorta of WHHL rabbits, resulting in the formation of foam cells laden with cholesterol esters. This process is attenuated by drugs which reduce plasma cholesterol, but a further reduction in aortic atherosclerosis may require agents which prevent oxidative modification of LDL cholesterol. Watanabe et al31) reported that pravastatin decreased coronary atherosclerosis and xanthoma formation, but had no significant effect on aortic atherosclerosis in WHHL rabbits. These inbred rabbits had much higher baseline levels of cholesterol than ours and were treated earlier (at the age of 2-3 months) and for only 24 weeks. Our control rabbits showed minimal evidence of coronary atherosclerosis, indicating a marked variability in the severity and distribution of lesions in this animal model. However, the studies are in general agreement and indicate that inhibition of cholesterol synthesis by HMG-CoA reductase inhibitors is effective in decreasing serum lipids and vascular cholesterol deposition, even in animals that lack LDL receptors.
